← Search another drug
PatientPulse · by PatientPartner
Trikafta elexacaftor/tezacaftor/ivacaftor
High confidence
~52 public patient conversations and editorial pages analyzed (CFF community posts, patient blogs, CF forums, CF news commentary, and clinical/policy reporting)
Executive intelligence
The signal that moves starts & adherence
52%Positive sentiment in discussion
12,133FDA adverse-event reports
42%Flagged serious
58%Reports name female patients
The single most actionable insight: neuropsychiatric side effects (anxiety, depression, cognitive fog) are now the primary driver of Trikafta discontinuation in the corpus, yet most patients report their CF care team dismissed or minimized these symptoms until the label was updated.
- Trikafta delivers transformative pulmonary and quality-of-life gains for the majority of patients, with dramatic reductions in cough, exacerbations, and treatment burden reported within days of initiation.
- Neuropsychiatric effects including depression, anxiety, cognitive fog, and mood instability are the leading discontinuation driver in patient narratives, with many reporting years of misdiagnosis before label recognition.
- Weight gain and its downstream consequences (disordered eating, CFRD management complexity, metabolic syndrome risk) represent a rapidly emerging, poorly counseled unmet need as CF life expectancy extends.
- Access and cost anxiety (Medicare gap, $311K list price, insurer navigation) creates a distinct pre-initiation stress layer that peer support and Vertex GPS programs are positioned to address but incompletely resolve.